Page last updated: 2024-11-04

vorinostat and Recrudescence

vorinostat has been researched along with Recrudescence in 28 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"This study was undertaken to evaluate safety and pharmacokinetics and to determine treatment doses of vorinostat plus bortezomib in Japanese patients with relapsed or refractory multiple myeloma (MM)."9.22A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. ( Ando, K; Hanson, ME; Hotta, T; Koh, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimamoto, T; Suzuki, T; Tanaka, Y; Tobinai, K; Uchida, T; Watanabe, T, 2016)
"The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents."9.22VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. ( Anderson, KC; Dimopoulos, M; Durrant, S; Eid, JE; Gause, C; Goldschmidt, H; Graef, T; Houp, J; Jagannath, S; Kaufman, JL; Leleu, X; Nagler, A; Offner, F; Siegel, DS; Vuocolo, S, 2016)
"Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles."9.20A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015)
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2."9.17A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013)
"To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)."9.16Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012)
" on days 1, 4, 8, and 11 and vorinostat at 100 to 500 mg orally daily for 8 days of each 21-day cycle in relapsed/refractory multiple myeloma patients."9.14Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ( Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J, 2009)
"This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone."7.83Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016)
"Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib."7.76Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010)
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established."6.80Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015)
"The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT)."5.24Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. ( Braun, T; Choi, SW; Dinarello, CA; Gatza, E; Henig, I; Magenau, J; Parkin, B; Pawarode, A; Reddy, P; Riwes, M; Yanik, G, 2017)
"This study was undertaken to evaluate safety and pharmacokinetics and to determine treatment doses of vorinostat plus bortezomib in Japanese patients with relapsed or refractory multiple myeloma (MM)."5.22A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. ( Ando, K; Hanson, ME; Hotta, T; Koh, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimamoto, T; Suzuki, T; Tanaka, Y; Tobinai, K; Uchida, T; Watanabe, T, 2016)
"The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents."5.22VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. ( Anderson, KC; Dimopoulos, M; Durrant, S; Eid, JE; Gause, C; Goldschmidt, H; Graef, T; Houp, J; Jagannath, S; Kaufman, JL; Leleu, X; Nagler, A; Offner, F; Siegel, DS; Vuocolo, S, 2016)
"Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles."5.20A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015)
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2."5.17A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013)
"To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)."5.16Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012)
" on days 1, 4, 8, and 11 and vorinostat at 100 to 500 mg orally daily for 8 days of each 21-day cycle in relapsed/refractory multiple myeloma patients."5.14Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ( Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J, 2009)
"This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone."3.83Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016)
"Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib."3.76Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010)
" We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL."2.82Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. ( Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016)
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established."2.80Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015)
"Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity."2.80A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. ( Chen, R; Forman, SJ; Frankel, P; Htut, M; Kirschbaum, M; Mott, M; Nademanee, A; Nathwani, N; Popplewell, L; Rotter, A; Ruel, N; Siddiqi, T; Thomas, SH, 2015)
"Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)."2.80Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015)
" In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL."2.79Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. ( Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014)
"To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts."2.78Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. ( Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M, 2013)
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied."2.78A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. ( Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013)
" HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro."2.75A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. ( Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010)
"Vorinostat was well tolerated at 300 mg b."2.73Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. ( Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008)
"Vorinostat (Zolinza) is a histone deacetylase inhibitor that has demonstrated activity in patients with advanced solid tumors in phase I trials."2.73Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. ( Chen, C; Dumez, H; Randolph, SS; Ricker, JL; Schöffski, P; Van Cutsem, E; Vansteenkiste, J, 2008)
"A number of new agents in acute myeloid leukemia (AML) have held much promise in recent years, but most have failed to change the therapeutic landscape."2.49New agents: great expectations not realized. ( Lancet, JE, 2013)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (10.71)29.6817
2010's22 (78.57)24.3611
2020's3 (10.71)2.80

Authors

AuthorsStudies
Alatrash, G1
Saberian, C1
Bassett, R1
Thall, PF2
Ledesma, C1
Lu, Y1
Daher, M1
Valdez, BC2
Kawedia, J1
Popat, U2
Mehta, R1
Oran, B1
Nieto, Y2
Olson, A1
Anderlini, P2
Marin, D1
Hosing, C2
Alousi, AM1
Shpall, EJ3
Rondon, G1
Chen, J1
Qazilbash, M2
Champlin, RE1
Kebriaei, P1
Janku, F1
Park, H1
Call, SG1
Madwani, K1
Oki, Y2
Subbiah, V1
Hong, DS1
Naing, A1
Velez-Bravo, VM1
Barnes, TG1
Hagemeister, FB1
Falchook, GS1
Karp, DD1
Wheler, JJ1
Piha-Paul, SA1
Garrido-Laguna, I1
Fayad, LE1
Neelapu, SS1
Meric-Bernstam, F1
Kurzrock, R1
Fanale, MA1
Brown, S1
Pawlyn, C1
Tillotson, AL1
Sherratt, D1
Flanagan, L1
Low, E1
Morgan, GJ1
Williams, C1
Kaiser, M1
Davies, FE1
Jenner, MW1
Choi, SW1
Braun, T2
Henig, I1
Gatza, E1
Magenau, J1
Parkin, B1
Pawarode, A1
Riwes, M1
Yanik, G1
Dinarello, CA1
Reddy, P1
Gojo, I1
Tan, M1
Fang, HB1
Sadowska, M1
Lapidus, R1
Baer, MR2
Carrier, F1
Beumer, JH1
Anyang, BN1
Srivastava, RK1
Espinoza-Delgado, I4
Ross, DD1
Holkova, B1
Supko, JG1
Ames, MM2
Reid, JM2
Shapiro, GI1
Perkins, EB1
Ramakrishnan, V1
Tombes, MB1
Honeycutt, C1
McGovern, RM2
Kmieciak, M1
Shrader, E1
Wellons, MD1
Sankala, H1
Doyle, A1
Wright, J1
Roberts, JD1
Grant, S2
Hummel, TR1
Wagner, L1
Ahern, C1
Fouladi, M1
Gilbertson, RJ1
Horton, T1
Ingle, AM1
Weigel, B1
Blaney, SM1
Prebet, T1
Beyne-Rauzy, O1
Dreyfus, F1
Stammatoullas, A1
Wattel, E1
Ame, S1
Raffoux, E1
Delaunay, J1
Charbonnier, A1
Adès, L1
Fenaux, P1
Vey, N1
Walter, RB1
Medeiros, BC1
Gardner, KM1
Orlowski, KF1
Gallegos, L1
Scott, BL1
Hendrie, PC1
Estey, EH1
Lancet, JE1
Hopfinger, G1
Nösslinger, T1
Lang, A1
Linkesch, W1
Melchardt, T1
Weiss, L1
Egle, A1
Greil, R1
Ogura, M2
Ando, K2
Suzuki, T2
Ishizawa, K1
Oh, SY1
Itoh, K1
Yamamoto, K2
Au, WY1
Tien, HF1
Matsuno, Y1
Terauchi, T1
Mori, M1
Tanaka, Y2
Shimamoto, T2
Tobinai, K2
Kim, WS2
Hofmeister, CC1
Williams, N1
Geyer, S1
Hade, EM1
Bowers, MA1
Earl, CT1
Vaughn, J1
Bingman, A1
Humphries, K1
Lozanski, G1
Baiocchi, RA1
Jaglowski, SM1
Blum, K1
Porcu, P1
Flynn, J1
Penza, S1
Benson, DM1
Andritsos, LA1
Devine, SM1
Straus, DJ1
Hamlin, PA1
Matasar, MJ1
Lia Palomba, M1
Drullinsky, PR1
Zelenetz, AD1
Gerecitano, JF1
Noy, A1
Hamilton, AM1
Elstrom, R1
Wegner, B1
Wortman, K1
Cella, D1
Chen, R1
Frankel, P1
Popplewell, L1
Siddiqi, T1
Ruel, N1
Rotter, A1
Thomas, SH1
Mott, M1
Nathwani, N1
Htut, M1
Nademanee, A1
Forman, SJ1
Kirschbaum, M1
How, J1
Minden, MD1
Brian, L1
Chen, EX1
Brandwein, J1
Schuh, AC1
Schimmer, AD1
Gupta, V1
Webster, S1
Degelder, T1
Haines, P1
Stayner, LA1
McGill, S1
Wang, L1
Piekarz, R1
Wong, T1
Siu, LL1
Holleran, JL3
Egorin, MJ3
Yee, KW1
Ahmed, S1
Jones, RB1
Gulbis, A1
Alousi, A1
Shah, N1
Bashir, Q1
Liu, Y1
Hagemeister, F1
Fanale, M1
Dabaja, B1
Pinnix, C1
Champlin, R1
Andersson, BS1
Ogawa, Y1
Watanabe, T1
Ohmachi, K1
Uchida, T1
Hanson, ME1
Koh, Y1
Hotta, T1
Shin, DY1
Kim, SJ1
Yoon, DH1
Park, Y1
Kong, JH1
Kim, JA1
Kim, BS1
Kim, HJ1
Won, JH1
Park, SK1
Siegel, DS2
Dimopoulos, M1
Jagannath, S2
Goldschmidt, H1
Durrant, S1
Kaufman, JL1
Leleu, X1
Nagler, A1
Offner, F1
Graef, T2
Eid, JE1
Houp, J1
Gause, C1
Vuocolo, S1
Anderson, KC2
Bilotti, E1
Vesole, DH2
McBride, L1
Schmidt, L1
Gao, Z1
Gilani, M1
McNeill, A1
Bednarz, U1
Richter, J1
Mato, A1
Badros, A1
Burger, AM1
Philip, S1
Niesvizky, R1
Kolla, SS1
Goloubeva, O1
Harris, C1
Zwiebel, J1
Wright, JJ1
Mazumder, A1
Kadia, TM2
Yang, H2
Ferrajoli, A1
Maddipotti, S1
Schroeder, C1
Madden, TL1
Ravandi, F2
Thomas, DA1
Newsome, W1
Sanchez-Gonzalez, B1
Zwiebel, JA1
Kantarjian, HM2
Garcia-Manero, G2
Tambaro, FP1
Bekele, NB1
Jabbour, E1
Borthakur, G1
Konopleva, MY1
Faderl, S1
Cortes, JE1
Brandt, M1
Hu, Y1
McCue, D1
Newsome, WM1
Pierce, SR1
de Lima, M1
Alsina, M1
Bensinger, W1
Biermann, JS1
Cohen, AD1
Devine, S1
Djulbegovic, B1
Faber, EA1
Gasparetto, C1
Hernandez-Illizaliturri, F1
Huff, CA1
Kassim, A1
Krishnan, AY1
Liedtke, M1
Meredith, R1
Raje, N1
Schriber, J1
Singhal, S1
Somlo, G1
Stockerl-Goldstein, K1
Treon, SP1
Weber, D1
Yahalom, J1
Yunus, F1
Shead, DA1
Kumar, R1
Crump, M1
Coiffier, B1
Jacobsen, ED1
Sun, L1
Ricker, JL2
Xie, H1
Frankel, SR1
Randolph, SS2
Cheson, BD1
Vansteenkiste, J1
Van Cutsem, E1
Dumez, H1
Chen, C1
Schöffski, P1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer[NCT01087554]Phase 1249 participants (Anticipated)Interventional2010-03-31Active, not recruiting
A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma[NCT01720875]Phase 216 participants (Actual)Interventional2013-08-09Completed
Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant[NCT01790568]Phase 226 participants (Actual)Interventional2014-12-31Completed
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors[NCT01076530]Phase 127 participants (Actual)Interventional2010-02-28Completed
A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes[NCT00776503]Phase 1/Phase 252 participants (Actual)Interventional2008-05-31Completed
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML)[NCT00895934]Phase 1/Phase 252 participants (Actual)Interventional2009-05-31Completed
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926]Phase 1/Phase 291 participants (Anticipated)Interventional2020-06-10Recruiting
A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)[NCT00875056]Phase 256 participants (Actual)Interventional2009-04-15Completed
Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma[NCT00561418]Phase 123 participants (Actual)Interventional2007-11-30Completed
A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma[NCT00720876]Phase 230 participants (Actual)Interventional2008-07-23Completed
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173]Phase 178 participants (Actual)Interventional2011-08-31Completed
A Multicenter, Open-Label, Phase I Study of MK-0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma[NCT00858234]Phase 19 participants (Actual)Interventional2009-02-13Completed
An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma[NCT00773838]Phase 2143 participants (Actual)Interventional2008-12-01Completed
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00097929]Phase 218 participants (Actual)Interventional2005-05-01Completed
A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.[NCT00126451]Phase 216 participants (Actual)Interventional2004-12-01Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Non-Relapse Mortality Incidence

(NCT01790568)
Timeframe: 1 year

Interventionpercentage of patients (Number)
Vorinostat16

Percentage of Patients Alive at 1 Year

Overall survival at 1 Year. (NCT01790568)
Timeframe: 1 Year

Interventionpercentage of patients (Number)
Vorinostat76

Percentage of Patients That Experience Grade 2-4 GVHD Within 100 Days of Transplant

"GVHD Staging:~Grade 2: (Skin) Maculopapular rash 25-50% BSA, (Liver) bilirubin 3.1-6mg/dl, (Gut) 1000-1500 ml/day for adult and 20-30ml/kg/day for child.~Grade 3: (Skin) Maculopapular rash >50% BSA, (Liver) 6.1-15mg/dl, (Gut) >1500mg/day for adult and >30ml/kg/day for child.~Grade 4: (Skin) Generalized erythroderma plus bullous formation and desquamation >5% BSA, (Liver) >15mg/dl, (Gut) Severe abdominal pain with or without ileus, or grossly bloody stool." (NCT01790568)
Timeframe: 100 Days

Interventionpercentage of patients (Number)
Vorinostat22

Disease Relapse

(NCT00895934)
Timeframe: up to 2 years

InterventionParticipants (Count of Participants)
Phase 2/Selected Dose5

Number of Participants With Complete Remission

Efficacy Defined as Best Response Achieved During Study Treatment Measured by Complete Remission (CR) Rate (NCT00895934)
Timeframe: up to 3 years

InterventionParticipants (Count of Participants)
Phase 2/Selected Dose18

Number of Participants With Dose-limiting Toxicity (Phase I)

(NCT00895934)
Timeframe: 42 days

Interventionparticipants (Number)
Dose 10
Dose 20
Dose 30
Dose 41

Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose

(NCT00895934)
Timeframe: Up to 3 years

Interventionparticipants (Number)
Phase 1 Dose-Finding Cohorts 1-34
Phase 2/Selected Dose18

Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported. (NCT00875056)
Timeframe: Up to 536 days

InterventionParticipants (Count of Participants)
Follicular Lymphoma (FL)6
Indolent Non-FL B-NHL or MCL1
Other Disease2

Number of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented. (NCT00875056)
Timeframe: Up to approximately 29 months

InterventionParticipants (Count of Participants)
Follicular Lymphoma (FL)39
Indolent Non-FL B-NHL or MCL11
Other Disease6

Objective Response Rate (ORR)

ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented. (NCT00875056)
Timeframe: Up to 650 days

InterventionPercentage of participants (Number)
Follicular Lymphoma (FL)48.7
Indolent Non-FL B-NHL or MCL27.3

Time to Response for Relapsed/Refractory FL

Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011. (NCT00875056)
Timeframe: Up to 650 days

InterventionDays (Median)
Follicular Lymphoma (FL)NA

Time to Treatment Failure for Relapsed/Refractory FL

Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011. (NCT00875056)
Timeframe: Up to 650 days

InterventionDays (Median)
Follicular Lymphoma (FL)323

Duration of Response

Median follow up of living patients (NCT00561418)
Timeframe: Up to 5 years

Interventionmonths (Median)
Vorinostat (SAHA)23.2

Clinical Benefit

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00561418)
Timeframe: Up to 3 years

Interventionpatients (Number)
Complete Response (CR)Partial Response (PR)Stable Disease(SD)Not evaluable
Vorinostat (SAHA)13325

Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation

NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE (NCT00561418)
Timeframe: Up to 3 years

Interventionpatients (Number)
Fatigue (Grade 1, 2)Lymphopenia (Grade 1-4)Thrombocytopenia (Grade 1-3)Leukopenia (Grade 1-3)Anemia (Grade 1-3)
Vorinostat (SAHA)1211111010

Overall Response Rate (Complete and Partial Response)

Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment

Interventionpercentage of participants (Number)
Vorinostat and Rituximab46

Progression-free Survival

ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress elapse, up to 1 year after the start of treatment

InterventionMonths (Median)
Vorinostat and Rituximab29.2

Number of Participants With Grade 3 and 4 Toxicities

Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment

InterventionParticipants (Count of Participants)
Neutrophil count decreasedPlatelet count decreasedHemoglobin decreasedLymphocyte count decreasedHypotensionChillsFatigueDehydrationDiarrheaKidney infectionPneumoniaSepsisUrinary tract infectionLocalized edemaAlanine aminotransferase increasedAspartate aminotransferase increasedBlood glucose increasedSerum phosphate decreasedSerum potassium decreasedMuscle weaknessSyncopeHypoxiaPneumonitisThrombosisVascular access complication
Vorinostat and Rituximab3517219311211111332111141

Number of Participants With an Adverse Event (AE)

The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s). (NCT00858234)
Timeframe: Up to 346 days (up to 30 days after the final dose of study treatment)

InterventionParticipants (Count of Participants)
Vorinostat + Bortezomib9

Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1

The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase [ALT]/aspartate aminotransferase [AST]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days). (NCT00858234)
Timeframe: Up to 21 days

InterventionParticipants (Count of Participants)
Vorinostat + Bortezomib1

Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11

The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib. (NCT00858234)
Timeframe: Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11

InterventionµM*hr (Least Squares Mean)
Day 1Day 11
Vorinostat + Bortezomib5.415.84

Number of Participants Who Discontinued Study Treatment Due to an AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinued study treatment due to an AE were reported. (NCT00773838)
Timeframe: Up to approximately 18 months

InterventionParticipants (Count of Participants)
Vorinostat + Bortezomib28

Number of Participants Who Experienced an Adverse Event (AE)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experienced an AE were reported. (NCT00773838)
Timeframe: Up to approximately 22 months

InterventionParticipants (Count of Participants)
Vorinostat + Bortezomib142

Objective Response Rate (RR)

Objective RR was defined as percentage (%) of participants with complete response (CR: disappearance of original monoclonal (M) paraprotein from blood & urine on at least 2 determinations for at least 6 weeks (WKs) by immunofixation studies, <5% plasma cells in bone marrow on at least 1 determination, no increase in size/number of lytic bone lesions (LBLs) & disappearance of soft tissue plasmacytomas (STP) for at least 6 WKs on skeletal survey (SS) if available) or partial response (PR: ≥50% reduction in serum M protein for at least 2 determinations 6 WKs apart, if present, reduction in 24-hour urinary light chain excretion by ≥90% or ≤200 mg for at least 2 determinations 6 WKs apart, ≥50% reduction in STP size for at least 6 WKs, & no increase in size/number of LBLs on SS if available) as assessed by Independent Adjudication Committee (IAC) per European Blood & Marrow Transplant (EBMT) criteria. To report RR & 95% confidence intervals (CIs), exact test of binomial parameter was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)

InterventionPercentage of Participants (Number)
Vorinostat + Bortezomib11.3

Overall Survival (OS)

OS was defined as the time from allocation to death due to any cause. To report the median survival (in months) and the associated 95%CIs were reported using Kaplan-Meier method was used. Participants without documented death at the time of final analysis were censored at the date of the last follow up. (NCT00773838)
Timeframe: Up to approximately 40 months (through End of Trial data cut-off of 09-Apr-2012)

InterventionMonths (Median)
Vorinostat + Bortezomib11.23

PFS as Assessed by Investigator Per EBMT Criteria

PFS was defined as the time from allocation to the first documents PD as assessed by investigator per EBMT criteria or death due to any cause, whichever occurs first. PD: >25% increase in level of serum M-paraprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median PFS (in months) and associated 95%CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)

InterventionMonths (Median)
Vorinostat + Bortezomib2.83

Progression-Free Survival (PFS) as Determined by IAC Per EBMT Criteria

PFS was defined as the time from allocation to the first documents PD as determined by IAC per EBMT criteria or death due to any cause, whichever occurs first. PD: >25% increase in level of serum M-paraprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median PFS (in months) and associated 95%CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)

InterventionMonths (Median)
Vorinostat + Bortezomib3.13

Time To Disease Progression (TTP) as Determined by IAC Per EBMT Criteria

TTP was defined as the time from allocation to the first documented disease progression (PD) as determined by IAC per EBMT criteria or death due to myeloma, whichever occurred first. PD: >25% increase in level of serum Mparaprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median TTP (in months) and associated 95% CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)

InterventionMonths (Median)
Vorinostat + Bortezomib3.47

TTP as Assessed by Investigator Per EBMT Criteria

TTP was defined as the time from allocation to the first documented PD as assessed by investigator per EBMT criteria or death due to myeloma, whichever occurred first. PD: >25% increase in level of serum Mparaprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median TTP (in months) and associated 95% CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)

InterventionMonths (Median)
Vorinostat + Bortezomib3.07

Reviews

1 review available for vorinostat and Recrudescence

ArticleYear
New agents: great expectations not realized.
    Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:3

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzo

2013

Trials

24 trials available for vorinostat and Recrudescence

ArticleYear
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:8

    Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti

2022
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-01, Volume: 26, Issue:21

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brentuxi

2020
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Dexamethasone;

2021
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
    Blood, 2017, 10-12, Volume: 130, Issue:15

    Topics: Acetylation; Acute Disease; Adolescent; Adult; Aged; Demography; Feasibility Studies; Female; Graft

2017
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7

    Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo

2013
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

2013
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
    Leukemia research, 2014, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Do

2014
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
    Haematologica, 2014, Volume: 99, Issue:1

    Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo

2014
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Annals of hematology, 2014, Volume: 93, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy

2014
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    British journal of haematology, 2014, Volume: 165, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; CREB-Binding Protein; DNA Mutational

2014
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:4

    Topics: Administration, Oral; Adult; Aged; Child; Combined Modality Therapy; Diarrhea; Disease-Free Survival

2015
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    British journal of haematology, 2015, Volume: 168, Issue:5

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap

2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Haematologica, 2015, Volume: 100, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine

2015
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitab

2015
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr

2015
A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    International journal of hematology, 2016, Volume: 103, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2016
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acid

2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Resistance, Neoplasm; Female; Human

2016
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Aug-15, Volume: 15, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Respons

2009
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
    British journal of haematology, 2010, Volume: 150, Issue:1

    Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combi

2010
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-20, Volume: 30, Issue:18

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema

2012
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug

2008
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
    Investigational new drugs, 2008, Volume: 26, Issue:5

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neop

2008

Other Studies

3 other studies available for vorinostat and Recrudescence

ArticleYear
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
    Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hy

2016
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease

2010
Multiple myeloma, version 1.2013.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B

2013
chemdatabank.com